Belarus
Tuberculosis profile
| High MDR-TB burden |
Population  2013 9.4 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.85 (0.79–0.91) 9.1 (8.5–9.8)
Mortality (HIV+TB only) 0.085 (0.066–0.11) 0.91 (0.71–1.1)
Prevalence  (includes HIV+TB) 9.5 (4.9–16) 102 (52–168)
Incidence  (includes HIV+TB) 6.5 (5.8–7.5) 70 (62–80)
Incidence (HIV+TB only) 0.32 (0.29–0.38) 3.5 (3.1–4.1)
Case detection, all forms (%) 68 (59–77)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 35 (33–37) 55 (52–57)
MDR-TB cases among notified pulmonary
TB cases
1 100 (1 100–1 200) 690 (660–730)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 259   865
Pulmonary, clinically diagnosed 988   19
Extrapulmonary 330   9
       
Total new and relapse 4 470    
Previously treated, excluding relapses 389    
Total cases notified 4 859    
Among 4 470 new and relapse cases:
14 (<1%) cases aged under 15 years; male:female ratio: 2.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 145 (95%) 1 097 (86%) 3 242
Laboratory-confirmed RR-/MDR-TB cases     1 386
Patients started on MDR-TB treatment     2 154
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 859 (100)
HIV-positive TB patients 250 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 189 (76)
HIV-positive people screened for TB 7 822  
HIV-positive people provided with IPT 403  
Treatment success rate (%)
New and relapse cases registered in 2012 85
Previously treated cases, excluding relapse, registered in 2012 69
HIV-positive TB cases, all types, registered in 2012 64
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 15.5
Drug susceptibility testing (per 5 million population) 4.3
Sites performing Xpert MTB/RIF 8
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 19
% Funded domestically 39%
% Funded internationally 21%
% Unfunded 40%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-21 Data: www.who.int/tb/data